Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NOVN
Clasificación en acciones #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Precio por acción
$149.90
Última sincronización: 2026-09-18
Capitalización bursátil
$284.92B
Cambio (1 día)
-0.66%
Cambio (1 año)
21.93%
País
CH
Comercio Novartis AG (NOVN)

Categoría

Historial del precio de la acción de Novartis AG (NOVN)
Precio más alto de cierre: $155.10 el 2026-09-01

Precio más bajo de cierre: $19.02 el 1995-04-01
Historial del precio de la acción de Novartis AG desde 1995 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) 10.79%
2025 34.64%
2024 1.69%
2023 8.06%
2022 8.71%
2021 -8.14%
2020 -2.05%
2019 20.72%
2018 3.40%
2017 19.32%
2016 -17.48%
2015 -9.35%
2014 20.80%
2013 23.98%
2012 13.54%
2011 -2.30%
2010 4.11%
2009 15.79%
2008 -14.72%
2007 -4.76%
2006 10.95%
2005 6.32%
2004 13.45%
2003 19.37%
2002 4.81%
2001 -12.71%
2000 12.71%
1999 -56.75%
1998 15.24%
1997 58.59%
1996 48.26%
1995 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$1.15K 53.22%
US
$269.75 53.10%
US
$263.75 18.56%
US
$474.96 36.76%
CH
$146.40 79.61%
US